title: Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly.
authors.affiliation: Amsterdam.
authors.forename: Pieter
authors.initials: P
authors.lastname: van Eijsden
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009426:Netherlands
chemical_list: D000970:Antineoplastic Agents